Rilogrotug is under clinical development by AVEO Pharmaceuticals and currently in Phase I for Cancer Anorexia-Cachexia Syndrome. According to GlobalData, Phase I drugs for Cancer Anorexia-Cachexia Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rilogrotug LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rilogrotug overview

AV-380 is under development for treatment of cancer associated cachexia, metastatic colorectal cancer, metastatic pancreatic cancer. It acts by targeting growth differentiation factor 15 (GDF-15) which is also known as macrophage inhibitory cytokine-1. It is developed based on human response technology. It is administered through intravenous route.

AVEO Pharmaceuticals overview

AVEO Pharmaceuticals (AVEO), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products in the pipeline. The company develops products through strategic partnerships with other pharmaceutical companies. AVEO is headquartered in Boston, Massachusetts, the US.

For a complete picture of Rilogrotug’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.